Incyte Announces Decision to Discontinue JANUS Studies of Ruxolitinib plus Capecitabine in Patients with Advanced or Metastatic Pancreatic Cancer
Go back to Incyte Announces Decision to Discontinue JANUS Studies of Ruxolitinib plus Capecitabine in Patients with Advanced or Metastatic Pancreatic Cancer| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 103.66 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $103.66 | 52 Week High | $118.49 | |||
| Open | $103.66 | 52 Week Low | $55.00 | |||
| Day High | $103.66 | P/E | N/A | |||
| Day Low | $103.66 | EPS | $-0.56 | |||
| Volume | 613 | |||||
